About PT Sehat Masa Depan
An Indonesian health-technology consulting firm in Jakarta. Sehat masa depan means "the healthy future" — the firm exists to clear the regulatory and strategic path to it.
Why this firm exists
Good health products fail in Indonesia for reasons that have nothing to do with the product: a licence filed under the wrong assumptions, a distributor chosen for the wrong reasons, training that clinical audiences never believed, an AI claim without the evidence to hold it up. Each of those failures sits at a junction between clinical medicine, regulation, and technology — and most advisers stand on only one side of that junction.
PT Sehat Masa Depan was founded in 2025 to stand on all three at once — led by a physician who reads the regulation in the original, has worked inside pharma and digital health operations, and serves on the review side of the Ministry of Health's AI regulatory sandbox. Advisory only, by design — the firm never acts as distributor or licence holder, so its advice about distributors and licences is never advice about itself.
The firm at a glance
- Legal entity — PT Sehat Masa Depan, a domestic investment (PMDN) limited liability company · NIB 3108250035296 · KBLI 70209 & 62015
- Founded — 2025, Jakarta. Based in Pancoran, Jakarta Selatan
- What we do — regulatory advisory, digital health strategy, capacity building, and AI & data governance, plus a product studio for digital builds
- How we're built — a deliberately small senior core, extended with specialist sub-consultants per engagement where the work needs them
- Working languages — Indonesian and English
How we work
- Senior-led, always. The people described on this page are the people who do the work — no junior handoffs behind a senior pitch.
- Advisory, not distribution. We never hold client licences or act as the distributor, so recommendations about partners are independent by construction.
- Sources cited, in writing. Deliverables name the governing regulation so you can check the basis of anything we tell you.
- Conflicts mean recusal. Where a conflict of interest would arise on a specific assessment, we recuse rather than manage it.
- Honest early answers. If we can't help, we say so in the first call — and point you to someone who can.
Leadership
Who you would actually work with — introduced properly on the first call.
Founder & Director
A medical doctor (Universitas Indonesia) with 15 years across pharma, digital health and government — including medical affairs and real-world-evidence work at Roche, AstraZeneca, Daiichi Sankyo, Alodokter and Nestlé. Author on 60+ scientific publications. Serves as an active External Evaluator of the Kemenkes AI Regulatory Sandbox and designs training delivered through Ministry of Health e-learning programmes.
Partnerships
First point of contact for partnership enquiries — distributor and healthcare-institution outreach, and coordination of engagements from first meeting to delivery.
Want to know who you'd be working with?
You just met them. A first call is with the senior team, takes 30 minutes, and ends with a straight answer about whether we can help.
Book a consultation